GRAL Stock Risk & Deep Value Analysis
Grail Inc
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About GRAL Stock
We analyzed Grail Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GRAL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is GRAL Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for GRAL?
- ⚠
FDA regulatory delays or outright rejection of PMA application
- ⚠
Intensified competitive entry with comparable or superior MCED tests
- ⚠
Negative results from ongoing or future clinical trials
- ⚠
Need for significant equity financing leading to dilution
Unlock GRAL Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Grail Inc (GRAL) Do?
Market Cap
$3.57B
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,000
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Visit Grail Inc WebsiteIs GRAL Stock Undervalued?
Unlock the full AI analysis for GRAL
Get the complete DVR score, risk analysis, and more
Does GRAL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Grail's moat is durable due to the immense scientific and regulatory barriers to entry in multi-cancer early detection, requiring vast clinical trials, proprietary algorithms, and significant capital. Its first-mover status in data accumulation further strengthens this.
Moat Erosion Risks
- •Competitors developing superior or cheaper MCED technologies with faster regulatory pathways
- •Intellectual property challenges or expiration of key patents
- •Failure to achieve widespread clinical adoption and reimbursement, limiting data accumulation
GRAL Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive GRAL Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Updates on FDA PMA application progress for Galleri
- •Expansion of commercial partnerships for Galleri distribution and adoption
Medium-Term (6-18 months)
- •FDA PMA approval for the Galleri multi-cancer early detection test (primary catalyst)
- •Significant expansion of private and public payor reimbursement coverage for Galleri
- •Initiation of new clinical trials for broader indications or expanded use cases
Long-Term (18+ months)
- •Establishment of dominant market share in the multi-cancer early detection market
- •Successful international expansion of Galleri and pipeline products
- •Development and commercialization of next-generation diagnostic platforms
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GRAL?
- ✓
FDA PMA approval official announcement and timeline for commercial launch
- ✓
Acceleration in Galleri test adoption rates and reimbursement coverage expansion
- ✓
Improvements in cash burn trajectory and progress towards profitability
- ✓
New strategic partnerships with major healthcare systems or payors
Bull Case Analysis
See what could go right with Premium
Compare GRAL to Similar Stocks
See how Grail Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GRAL (Grail Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
